Newly developed retatrutide, a twin -action treatment targeting both GLP-1 and GIP receptors, is creating considerable buzz within the medical community. Preliminary clinical research have revealed substantial losses in physical size and gains in health markers for individuals with obesity . Researchers believe this novel approach could signify a